IOVANCE BIOTHERAPEUTICS, INC. (IOVA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US4622601007
IOVANCE BIOTHERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 263.50 m USD |
| Gross profit | 90.32 m USD |
| Operating income | -403.36 m USD |
| EBIT | -403.36 m USD |
| Net income | -390.98 m USD |
| Diluted EPS – continuing operations | -1.09 USD |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
More stocks
- APPIAN CORP (APPN)
- Andon Health Co Ltd (002432.SZ)
- Structure Therapeutics Inc. (GPCR)
- Fideicomiso Irrevocable F/2061 FHipo (FHIPO14.MX)
- Shanghai Moons' Elec Co Ltd (603728.SS)
- Monks Investment Trust PLC (MNKS.L)
- NICOLET BANKSHARES INC (NIC)
- Beijing Sifang Automation Co Ltd (601126.SS)
- Loomis AB (LOOMIS.ST)
- Ubtech Robotics Corp Ltd (9880.HK)
- Worley Ltd (WOR.AX)
- EquipmentShare.com Inc (EQPT)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.